Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin

References

• Gant V, Parton S. Community-acquired pneumonia. Curr Opin Pulm Med 2000;6:226–33
   PubMedGoogle Scholar
• Bartlett JG, Breiman RF, Mandell LA, File Jr. TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811–38
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820–37
   Google Scholar
• Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513–28
   Google Scholar
• Marston BJ, Plouffe JF, File Jr. TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997;157:1709–18
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–54
   Google Scholar
• Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78(Suppl 6B):45–51
   Google Scholar
• Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, epidemiology, and impact. Am J Med 1985;78:32–7
   PubMed Web of Science ®Google Scholar
• Spiritus EM, Chang RJ, Zhang JX, et al. Cost savings of clarithromycin compared with erythromycin or cefaclor in the treatment of lower respiratory tract infection: results of a randomized, multicenter study. Am J Manag Care 1998;4(Suppl 10):S562–S570
   Web of Science ®Google Scholar
• Mandell LA. Community-acquired pneumonia. Etiology, epidemiology, and treatment. Chest 1995;108(Suppl 2):S35–S42
   Google Scholar
• Bernstein JM. Treatment of community-acquired pneumonia – IDSA guidelines. Chest 1999;115(Suppl):9S–13S
   Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America. Clin Infect Dis 2003;37:1405–33
   Google Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399–408
   PubMed Web of Science ®Google Scholar
• Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383–421
   Google Scholar
• Felmingham D, Grüneberg RN, The Alexander Project Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45: 191–203
   Google Scholar
• Balfour JA, Figgitt DP. Telithromcyin. Drugs 2001;61:815–2
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002;62:1771–804
   PubMed Web of Science ®Google Scholar
• Carbon C. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults. Infection 2003;31:308–17
   PubMed Web of Science ®Google Scholar
• Aventis. Ketek (telithromycin). Briefing document for the FDA anti-infective drug products advisory committee meeting, January 2003. Available from http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf [Accessed 27 November 2003]
   Google Scholar
• Dunbar LM, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48–62
   Google Scholar
• Tellier G, Isakov T, Petermann W, Patel M, Lavin B. Efficacy and safety of telithromycin for 5 or 7 days vs clarithromycin for 10 days in the treatment of patients with community-acquired pneumonia [Abstract L373]. In: Abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology; 2002
   Google Scholar
• Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10days. Curr Med Res Opin 2004; 20(5):739–47
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243–50
   PubMed Web of Science ®Google Scholar
• American Hospital Association. Hospital Statistics. Data derived from responses to the 1999 American Hospital Association Annual Survey. In: Hospital statistics, 2001 ed. Chicago: Health Forum LLC, an affiliate of the American Hospital Association; 2001
   Google Scholar
• Mandell L, Chang J, Oster G, et al. Comparison of healthcare utilization in patients with acute exacerbations of chronic bronchitis (AECB) receiving telithromycin (TEL) versus clarithromycin (CLA) in a randomized, double-blind, multicenter clinical trial [Abstract L1595]. In: Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology; 2003
   Google Scholar
• Chang JR, Stewart J, Cadilhac M, Nieman RB. Telithromycin (TEL) results in fewer hospitalizations than amoxicillin–clavulanate (AMC) in the outpatient treatment of acute exacerbations of chronic bronchitis (AECB). Value Health 2003;6:250–1
   Web of Science ®Google Scholar